Skip to main content

Clolar Side Effects

Generic name: clofarabine

Medically reviewed by Drugs.com. Last updated on Mar 29, 2023.

Note: This document contains side effect information about clofarabine. Some dosage forms listed on this page may not apply to the brand name Clolar.

Applies to clofarabine: intravenous solution.

Serious side effects of Clolar

Along with its needed effects, clofarabine (the active ingredient contained in Clolar) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking clofarabine:

More common

Less common

Incidence not known

Other side effects of Clolar

Some side effects of clofarabine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to clofarabine: intravenous solution.

Gastrointestinal

Very common (10% or more): Vomiting (78%), nausea (73%), diarrhea (56%), abdominal pain (35%), gingival or mouth bleeding (17%), mucosal inflammation (16%)

Common (1% to 10%): Upper abdominal pain, oral mucosal petechiae, proctalgia, stomatitis, cecitis, pancreatitis

Postmarketing reports: GI hemorrhage (including fatalities)[Ref]

Other

Very common (10% or more): Pyrexia (39%), chills (34%), fatigue (34%), pain (15%), edema (12%), asthenia (10%)[Ref]

Hematologic

Very common (10% or more): Leukopenia (88%), anemia (83%), lymphopenia (82%), thrombocytopenia (81%), neutropenia (64%), febrile neutropenia (55%), nonfebrile neutropenia (10%)[Ref]

Dermatologic

Very common (10% or more): Pruritus (43%), rash (38%), petechiae (26%), palmar-plantar erythrodysesthesia syndrome (16%), erythema (11%)

Common (1% to 10%): Rash pruritic

Postmarketing reports: Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) (including fatal cases)[Ref]

Nervous system

Very common (10% or more): Headache (43%), anxiety (21%), lethargy (10%), somnolence (10%)

Common (1% to 10%): Agitation[Ref]

Hepatic

Very common (10% or more): SGPT elevated (81%), SGOT elevated (74%), bilirubin elevated (45%)

Common (1% to 10%): Jaundice, hyperbilirubinemia[Ref]

Cardiovascular

Very common (10% or more): Tachycardia (35%), hypotension (29%), flushing (19%), hypertension (13%)

Common (1% to 10%): Pericardial effusion[Ref]

Respiratory

Very common (10% or more): Epistaxis (27%), dyspnea (13%), pleural effusion (12%), pneumonia (10%), respiratory distress (10%), respiratory syncytial virus infection, sinusitis

Common (1% to 10%): Upper respiratory tract infection, tachypnea, pulmonary edema[Ref]

Musculoskeletal

Very common (10% or more): Pain in extremity (34%), myalgia (16%), back pain (12%), bone pain (11%)

Common (1% to 10%): Arthralgia[Ref]

Psychiatric

Very common (10% or more): Irritability (11%)

Common (1% to 10%): Mental status change[Ref]

Genitourinary

Very common (10% or more): Hematuria (13%)[Ref]

Renal

Very common (10% or more): Creatinine elevated (50%)[Ref]

Oncologic

Common (1% to 10%): Tumor lysis syndrome[Ref]

Hypersensitivity

Common (1% to 10%): Hypersensitivity[Ref]

Immunologic

Very common (10% or more): Sepsis, including septic shock (17%), catheter related infection (12%), herpes simplex (10%)

Common (1% to 10%): Clostridium colitis, bacteremia, staphylococcal bacteremia, staphylococcal sepsis, candidiasis, cellulitis, herpes zoster, oral candidiasis, bacterial infection, enterococcal bacteremia, escherichia bacteremia, escherichia sepsis, fungal infection, fungal sepsis, gastroenteritis adenovirus, infection, influenza, parainfluenza virus infection, pneumonia fungal, pneumonia primary atypical, staphylococcal infection[Ref]

Metabolic

Very common (10% or more): Anorexia (30%)

Postmarketing reports: Hyponatremia[Ref]

References

1. Product Information. Clolar (clofarabine). sanofi-aventis. 2005.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.